BerganKDV Wealth Management’s Pacira BioSciences PCRX Stock Holding History

BerganKDV Wealth Management’s Portfolio PCRX Stock Details PCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-14	Closed	-$1K	–	1081
2021 Q2	$1K	Hold	14	–	–	﹤0.01%	938
2021 Q1	$1K	Hold	14	–	–	﹤0.01%	884
2020 Q4	$1K	Hold	14	–	–	﹤0.01%	888
2020 Q3	$1K	Hold	14	–	–	﹤0.01%	846
2020 Q2	$1K	Hold	14	–	–	﹤0.01%	888
2020 Q1	$0	Hold	14	–	–	﹤0.01%	985
2019 Q4	$1K	Hold	14	–	–	﹤0.01%	885
2019 Q3	$1K	Hold	14	–	–	﹤0.01%	677
2019 Q2	$1K	Hold	14	–	–	﹤0.01%	718
2019 Q1	$1K	Hold	14	–	–	﹤0.01%	711
2018 Q4	$1K	Hold	14	–	–	﹤0.01%	674
2018 Q3	$1K	Hold	14	–	–	﹤0.01%	608
2018 Q2	$0	Buy	+14	New	+$483	﹤0.01%	651

Other funds holding PCRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

SCM

Spyglass Capital Management San Francisco, California $1.41B AUM 7.96% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return

BerganKDV Wealth Management's PCRX Position: Q3 2021 in Review

BerganKDV Wealth Management sold out of Pacira BioSciences (PCRX) in Q3 2021, closing a stake of 14 shares — an estimated $1K sold.

BerganKDV Wealth Management first reported a position in PCRX in Q2 2018 and held it in 13 quarters. The position peaked at $1K in Q2 2021. 259 funds tracked by Wall St. Rank hold PCRX as of Q3 2021.

BerganKDV Wealth Management reported no remaining Pacira BioSciences position as of Q3 2021 after selling out during the quarter.
BerganKDV Wealth Management sold 14 Pacira BioSciences shares in Q3 2021, an estimated $1K.
BerganKDV Wealth Management first reported a position in Pacira BioSciences in Q2 2018 and held it in 13 quarters.
BerganKDV Wealth Management's Pacira BioSciences position peaked at $1K in Q2 2021.
259 funds tracked by Wall St. Rank held Pacira BioSciences as of Q3 2021.

Based on BerganKDV Wealth Management's 13F filing for Q3 2021, filed 12 Nov 2021.